Abbott Laboratories announced its 410th consecutive quarterly dividend of 63 cents per share, payable on August 17, 2026. The company has increased its dividend for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index.

Beyond Meat has launched Beyond Immerse protein drinks to counter declining plant-based meat sales, which fell 16% in 2025. The company faces significant financial challenges with $333 million in operating losses and must compete against industry giants like PepsiCo, Coca-Cola, and Abbott Laboratories in the $35 billion protein drink market. Analysts remain skeptical about whether this pivot can turn around the struggling company, noting the limited-time nature of the product launch and lack of early financial improvements.

Grail, a leader in multi-cancer early detection (MCED) testing, could be poised for significant growth as its Galleri test shows promising clinical trial results. The company awaits FDA approval and potential insurance reimbursement, which could unlock a $50 billion market opportunity. However, the stock remains high-risk due to unprofitability and competition from larger players.

A federal judge ruled that Abbott Laboratories must defend against a class-action lawsuit alleging it misled consumers about PediaSure Grow & Gain drinks. The judge found that Abbott's marketing, including packaging with a giraffe and ruler markings, could reasonably be interpreted as promising height growth, despite the company's claims only stating the product helps kids 'grow' without specifying the type of growth.

The global chemiluminescence immunoassay (CLIA) market is projected to grow from USD 11.58 billion in 2026 to USD 16.39 billion by 2031, with a CAGR of 7.2%. Growth is driven by rising demand for high-sensitivity diagnostic testing, automated laboratory systems, increasing prevalence of chronic and infectious diseases, and technological advancements including AI-enabled automation. Asia Pacific is emerging as a high-growth region, while hospitals lead market adoption.

The global non-invasive blood glucose monitoring devices market is projected to grow from USD 34.86 million in 2024 to USD 340.49 million by 2034, with a CAGR of 25.60%. Growth is driven by rising diabetes prevalence, increasing demand for painless monitoring, and technological advancements in wearables and optical sensing. Spectroscopy technology and homecare segments are expected to lead the market, while North America will dominate regionally.

Warren Buffett and Greg Abel's Berkshire Hathaway portfolio is notably absent from the healthcare sector, holding only DaVita and recently exiting UnitedHealth Group. The article argues investors should consider healthcare independently, as it offers opportunities across multiple investment styles—from high-growth pharma/biotech plays like Eli Lilly to dividend-paying stalwarts like Johnson & Johnson and Abbott Laboratories that provide steady earnings and income.

The global protein supplements market is projected to grow from USD 30.30 billion in 2026 to USD 43.98 billion by 2031, driven by mainstream fitness adoption, plant-based innovations, RTD products, and rapid Asia-Pacific expansion. Growth is supported by social media influence, sports sponsorships, technological advancements in protein extraction, and expanding consumer segments beyond traditional athletes.

The global peripheral vascular devices market is projected to grow from USD 10.02 billion in 2026 to USD 13.22 billion by 2031 at a CAGR of 5.7%, driven by rising prevalence of vascular disorders, aging populations, and innovations in minimally invasive devices. Asia Pacific is expected to see the highest growth, with major players including Boston Scientific, Medtronic, and Abbott leading the market.

Despite recent declines, three healthcare stocks—Intuitive Surgical, HCA Healthcare, and Abbott Laboratories—are positioned as long-term buy-and-hold opportunities. While facing macroeconomic headwinds and near-term challenges, each company has strong underlying fundamentals, innovative products, and exposure to growing healthcare trends that could drive significant long-term returns.

JenaValve Technology announced the appointment of Edward Sarnowski as Chief Technology Officer to lead R&D and drive innovation following FDA approval of its Trilogy Transcatheter Heart Valve System for severe aortic regurgitation. Sarnowski brings over 20 years of medical device R&D leadership experience from Medtronic and St. Jude Medical, with expertise in structural heart and transcatheter valve technologies.

Johnson & Johnson is highlighted as a superior Dividend King investment compared to peers like Procter & Gamble, offering better dividend growth (5.7% vs 2.4% annualized) and business resilience. Despite trading at a premium valuation, J&J's diversified pharmaceutical and medical device portfolio, patent protections, and essential healthcare products make it well-positioned to weather economic uncertainty.